ATE249211T1 - Behandlung von metastasierendem nicht auf hormonbehandlung ausprechendem prostatakrebs - Google Patents

Behandlung von metastasierendem nicht auf hormonbehandlung ausprechendem prostatakrebs

Info

Publication number
ATE249211T1
ATE249211T1 AT95902723T AT95902723T ATE249211T1 AT E249211 T1 ATE249211 T1 AT E249211T1 AT 95902723 T AT95902723 T AT 95902723T AT 95902723 T AT95902723 T AT 95902723T AT E249211 T1 ATE249211 T1 AT E249211T1
Authority
AT
Austria
Prior art keywords
treatment
prostate cancer
metastasic
responsible
cyclophosphamide
Prior art date
Application number
AT95902723T
Other languages
English (en)
Inventor
Lorne J Brandes
Original Assignee
Univ Manitoba
Manitoba Cancer Treat And Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Manitoba Cancer Treat And Res filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE249211T1 publication Critical patent/ATE249211T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT95902723T 1993-12-27 1994-12-07 Behandlung von metastasierendem nicht auf hormonbehandlung ausprechendem prostatakrebs ATE249211T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,047 US5432168A (en) 1993-12-27 1993-12-27 Method of treatment of hormone-unresponsive metastatic prostate cancer
PCT/CA1994/000676 WO1995017887A1 (en) 1993-12-27 1994-12-07 Method of treatment of hormone-unresponsive metastatic prostate cancer

Publications (1)

Publication Number Publication Date
ATE249211T1 true ATE249211T1 (de) 2003-09-15

Family

ID=22630304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902723T ATE249211T1 (de) 1993-12-27 1994-12-07 Behandlung von metastasierendem nicht auf hormonbehandlung ausprechendem prostatakrebs

Country Status (9)

Country Link
US (1) US5432168A (de)
EP (1) EP0737067B1 (de)
JP (1) JP3194525B2 (de)
AT (1) ATE249211T1 (de)
AU (1) AU699798B2 (de)
CA (1) CA2179377C (de)
DE (1) DE69433140T2 (de)
ES (1) ES2210278T3 (de)
WO (1) WO1995017887A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) * 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5863912A (en) * 1994-12-07 1999-01-26 Manitoba Cancer Treatment And Research Foundation Method of treatment of hormone-unresponsive metastiatic prostate cancer
US6241962B1 (en) 1996-06-24 2001-06-05 Dupont Pharmaceuticals Company Radiopharmaceutical compositions and matrices and uses thereof
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829068A (en) * 1987-03-18 1989-05-09 University Of Manitoba Treatment of disorders of the gastro-intestinal tract
CA1334752C (en) * 1988-08-02 1995-03-14 Ryozo Sakoda Drug effect-enhancing agent for antitumor drug
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
WO1992011035A1 (en) * 1990-12-17 1992-07-09 University Of Manitoba Improved treatment method for cancer
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment

Also Published As

Publication number Publication date
AU699798B2 (en) 1998-12-17
AU1188995A (en) 1995-07-17
EP0737067B1 (de) 2003-09-10
JPH09506902A (ja) 1997-07-08
DE69433140D1 (de) 2003-10-16
ES2210278T3 (es) 2004-07-01
JP3194525B2 (ja) 2001-07-30
CA2179377C (en) 2005-01-25
CA2179377A1 (en) 1995-07-06
DE69433140T2 (de) 2004-07-08
EP0737067A1 (de) 1996-10-16
WO1995017887A1 (en) 1995-07-06
US5432168A (en) 1995-07-11

Similar Documents

Publication Publication Date Title
AU747599C (en) Antitumor agents
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
KR930009607A (ko) 증식성 질환의 치료를 위한 다이피리다몰
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
GEP20063773B (en) Steroid Sulphatase Inhibitors
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
KR930701175A (ko) 인체 전립선 아데노카르시노마의 치료방법
ATE174785T1 (de) Behandlung von akne oder von folliculitis barbae
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE249211T1 (de) Behandlung von metastasierendem nicht auf hormonbehandlung ausprechendem prostatakrebs
FR2092743A1 (en) Complete extraction of total flavanol gomers from plats -peripheral - venous activity
DE69103693D1 (de) Behandlung von unterirdischen Formationen.
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
DE3770766D1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
BG51145A3 (bg) Инсекто-акарицидно средство и метод за борба с инсекти и акари по растенията
DE69218200D1 (de) Behandlung von leberkrebs
DE69924979D1 (de) Behandlung von chronischen schmerzen
NO992985D0 (no) Anvendelse av COMT inhibitorer for fremstilling av et legemiddel til Õ forhindre diabetisk vaskulµr dysfunksjon
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
KR970025616A (ko) 인삼 진세노사이드를 함유하는 항통증제

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties